Molecules and Cells

Korean Society for Molecular and Cellular Biology (한국분자세포생물학회)
권호 표지

Combined Effect of Heptaplatin and Ionizing Radiation on Human Squamous Carcinoma Cell Lines

  • Ryu, Mi-Ryeong (Department of Radiation Oncology, College of Medicine, The Catholic University of Korea) ;
  • Paik, Soon-Young (Department of Microbiology, College of Medicine, The Catholic University of Korea) ;
  • Chung, Su-Mi (Department of Radiation Oncology, College of Medicine, The Catholic University of Korea)
  • Received : 2004.10.18
  • Accepted : 2004.11.11
  • Published : 2005.02.28
⟨ Previous Next ⟩

Abstract

Heptaplatin, cis-malonato [(4R,5R)-4,5-bis (amino-methyl)-2-isopropyl-1,3-dioxolane] platinum(II) (SKI-2053R, Sunpla) is a new platinum derivative with antitumor activity comparable to cisplatin on various cancer cell lines. Preclinical studies suggest that it is less nephrotoxic than cisplatin. This study was undertaken to examine the combined effect of heptaplatin and ionizing radiation on two established human squamous carcinoma cell lines (NCI-H520, SQ20B). The cytotoxic activity of heptaplatin was concentration-dependent in both cell lines. When low dose heptaplatin was combined with high dose ionizing radiation, there was an additive cytotoxic effect on NCI-H520 cells (P < 0.05), while a moderate dose of heptaplatin and a low dose of ionizing radiation had an additive cytotoxic effect on the growth of SQ20B cells (P < 0.05). FACS analysis and DAPI staining showed that their additive cytotoxic effects were correlated with the induction of apoptosis. Further studies are warranted using heptaplatin and ionizing radiation in squamous cell carcinoma as a substitute for cisplatin.

Keywords

Acknowledgement

Supported by : Ministry of Health & Welfare

References

  1. Ahn, J. H., Kang, Y. K., Kim, T. W., Bahng, H., Chang, H. M., et al. (2002) Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. Cancer Chemother. Pharmacol. 50, 104-110 https://doi.org/10.1007/s00280-002-0483-x
  2. Berclaz, G., Gerber, E., Beer, K., Aebi, S., Greiner, R., et al. (2002) Long-term follow-up of concurrent radiotherapy and chemotherapy for locally advanced cervical cancer: 12-year survival after radiochemotherapy. Int. J. Oncol. 20, 1313-1318
  3. Carter, S. K. (1984) Cisplatin-past, present and future; in Platinum Coordination Complexes in Cancer Chemotherapy, Hacker, M. P., Douple, E. B., and Krakoff, I. H. (eds.), pp. 359-376, Martinus Nijhoff Publishing, Boston
  4. Coughlin, C. T. and Richmond, R. C. (1989) Biological and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin. Sem. Oncol. 16, 31-43
  5. Dewit, L. (1987) Combined treatment of radiation and cisdiamminedichloro-platinum (II): a review of experimental and clinical data. Int. J. Radiat. Oncol. Biol. Phys. 13, 403-426
  6. Durant, J. R. (1980) Cisplatin: a clinical overview; in Cisplatin, Current Status and New Developments, Prestayko, A. W., Crooke, S. T., and Carter, S. K. (eds.), pp. 317-321, Academic Press, New York, NY
  7. Eastman, A. (1999) The mechanism of action of cisplatin: from adducts to apoptosis; in Chemistry and Biochemistry of a Leading Anticancer Drug, Bernhard, L. (ed.), pp. 111-134, Wiley-VCH, Basel
  8. Fram, R. J. (1992) Cisplatin and platinum analogues: recent advances. Curr. Opin. Oncol. 4, 1073
  9. Furuse, K., Kubota, K., Kawahara, M., Kodama, N., Ogawara, M., et al. (1995) Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 13, 869-875
  10. Gonzalez, V. M., Fuertes, M. A., Alonso, C., and Perez, J. M. (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol. Parmacol. 59, 657-663
  11. Hong, W. S., Kim, H. T., Kim, K. H., and Kim, D. K. (1995) In vitro antitumor activity of a new platinum complex, cismalonato (4R, 5R)-4,5-bis(aminomethyl)-1,3-dioxolane-platinum (II) (SKI 2053R), against human lung and stomach cancer cell lines. Anticancer Res. 15, 51-54
  12. Joiner, M. C., Lambin, P., and Marples, B. (1999) Adaptive response and induced resistance. C. R. Acad. Sci. III. 322, 167-175
  13. Joiner, M. C., Marples, B., Lambin, P., Short, S. C., and Turesson, I. (2001) Low-dose hypersensitivity : current status and possible mechanisms. Int. J. Rad. Oncol. Biol. Phys. 49, 379-389 https://doi.org/10.1016/S0360-3016(00)01471-1
  14. Kalendo, G. S. (2001) Different levels of radiation protection in tumor cell populations. Radiats. Biol. Radioecol. 41, 519-527
  15. Kelland, L. R. (1993) New platinum antitumor complexes. Crit. Rev. Oncol./Hematol. 15, 191-219 https://doi.org/10.1016/1040-8428(93)90042-3
  16. Kim, D. K., Kim, G., Gam, J., Cho, Y. B., Kim, H. T., et al. (1994a) Synthesis and antitumor activity of a series of 2-substituted-4,5-bis(aminomethyl)-1,3-dioxolaneplatinum(II) complexes. J. Med. Chem. 37, 1471-1485 https://doi.org/10.1021/jm00036a013
  17. Kim, D. K., Ahn, J. S., Ryu, G., Kim, K. H., Park, C. W., et al. (1994b) General pharmacology of cis-malonato(4R,5R)-4,5-bi(aminomet- hyl)-1,3-dioxolane-platinum(II) (SKI 2053R). Arzneim. Forsch. 44, 1080-1088
  18. Kim, D. K., Kim, H. T., Tai, J. H., Cho, Y. B., Kim, T. S., et al. (1995a) Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato-(4R,5R)-4,5-bis (aminomethyl)-1,3-dioxolane-platinum(II), as determined by ex vivo pharmacodynamics. Cancer Chemother. Pharmacol. 37, 1-6
  19. Kim, D. K., Kim, H. T., Cho, Y. B., Tai, J. H., Ahn, J. S., et al. (1995b) Antitumor activity of cis-malonato(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane-platinum(II), a new platinum analogue, as an anticancer agent. Cancer Chemother. Pharmacol. 44, 441-445
  20. Kim, N. K., Im, S. A., Kim. D. W., Lee, M. H., Jung, C. W., et al. (1999) Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. Cancer 86, 1109-1115 https://doi.org/10.1002/(SICI)1097-0142(19991001)86:7<1109::AID-CNCR3>3.0.CO;2-G
  21. Kim, N. K., Kim, T. Y., Shin, S. G., Park, Y. L., Lee, J. A., et al. (2001) A phase I study of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-1,3-dioxolane]plaTINUM(II) in patients with advanced malignancies. Cancer 91, 1549-1556 https://doi.org/10.1002/1097-0142(20010415)91:8<1549::AID-CNCR1164>3.0.CO;2-2
  22. Kim, S. J., Kim, J. E., and Moon, I. S. (2004) Paraquat induces apoptosis of cultured rat cortical cells. Mol. Cells 17, 102-m107
  23. Kohno, N., Kitahara, S., Tamura, E., and Tanabe, T. (2002) Concurrent chemoradio-therapy with low-dose cisplatin plus 5-Fluorouracil for the treatment of patients with unresectable head and neck cancer. Oncology 63, 226-231 https://doi.org/10.1159/000065469
  24. Kokubo, M., Nagata, Y., Nishimura, Y., Kimura, H., Shoji, K., et al. (2001) Concurrent chemoradiotherapy for oropharyngeal carcinoma. Am. J. Clin. Oncol. 24, 71-m96 https://doi.org/10.1097/00000421-200102000-00013
  25. Lee, Y. S., Kang, K. S., Shin, D. J., Cho, J. J., Kim, H. O., et al. (1992) Subacute toxicity of cis-malonato(4R,5R)-4,5-bis-(aminomethyl)-1,3-dioxolane-platinum(II) (SKI 2053R) in beagle dogs. Korean J. Toxicol. 8, 235-m254
  26. Leichman, L., McDonald, B., Dindogru, F. A., Samson, M., and Vaitkevicius, V. K. (1984) An active drug in the treatment of disseminated gastric cancer. Cancer 53, 18-22 https://doi.org/10.1002/1097-0142(19840101)53:1<18::AID-CNCR2820530105>3.0.CO;2-J
  27. Loeher, P. J. and Einhorn, L. H. (1984) Drugs five years later. Cisplatin. Ann. Intern. Med. 100, 704
  28. Merlano, M., Corvo, R., Margarino, G., Benasso, M., Rosso, R., et al. (1991) Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial. Cancer 67, 915-921 https://doi.org/10.1002/1097-0142(19910215)67:4<915::AID-CNCR2820670410>3.0.CO;2-8
  29. Merlano, M., Vitale, V., Rosso, R., Benasso, M., Corvo, R., et al. (1992) Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N. Engl. J. Med. 327, 1115-m1121
  30. Muggia, F. M. and Norris, K. J. (1989) Future of cancer chemotherapy with cisplatin. Semin. Oncol. 16, 123
  31. Non-small lung cancer collaborative group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br. Med. J. 311, 889-890
  32. O'wyer, P. J., Johnson, S. W., and Hamilton, T. C. (1997) Pharmacology of cancer chemotherapy: cisplatin and its analogues; in Cancer: Principles and Practice of Oncology, De Vita, V. T., Hellman, S., and Rosenberg, S. A. (eds.), pp. 418-m432, Lippincott-Raven, Philadelphia
  33. Potish, R. A., Twiggs, L. B., and Adcock, L. L. (1986) Effect of cisplatinum on tolerance to radiation therapy in advanced cervical cancer. Am. J. Clin. Oncol. 9, 387-m391
  34. Reed, E., Dabholkar, M., and Chabner, B. A. (1996) Platinum analogues; in Cancer Chemotherapy and Biotherapy: Principles and Practice, Chabner, B. A. and Longo, D. I. (eds.), pp. 357, Lippincott-Raven, Philadelphia
  35. Rose, P. G. (2002) Chemoradiotherapy for cervical cancer. Eur. J. Cancer. 38, 270-278 https://doi.org/10.1016/S0959-8049(01)00352-5
  36. Rosenberg, B. (1999) Platinum complexes for the treatment of cancer: why the search goes on; in Cisplatin. In Chemistry and Biochemistry of a Leading Anticancer Drug, Bernhard, L. (ed.), pp. 3-m27, Wiley-VCH, Basel
  37. Sause, W. T., Scott, C., and Taylor, S. (1995) Radiation Therapy Oncology Group (RTOG 88-08) Eastern Cooperative Oncology Group (ECOG 4588): preliminary results of a phase III trial in regionally advanced unresectable nonsmall cell lung cancer with minimum three year follow-up (Abstr). Int. J. Rad. Oncol. Biol. Phys. 32, 109
  38. Schaake-Koning, C., van den Bogaert, W., Dalesio, O., Festen, J., Hoogenhout, J., et al. (1994) Radiosensitization by cytotoxic drugs. The EORTC experience by the Radiotherapy and Lung Cancer Cooperative Groups. Lung Cancer 10, 263-270 https://doi.org/10.1016/0169-5002(94)91690-X
  39. Soresi, E., Clerici, M., and Grilli, R. (1988) A randomized clinical trial comparing radiation therapy versus radiation therapy plus cis-dichlorodiamine (platinum III) in the treatment of locally advanced non-small cell lung cancer. Semin. Oncol. 15, 20-m25
  40. Steel, G. G. and Peckham, M. J. (1979) Exploitable mechanism in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys. 5, 85-m91
  41. Tannock, I. F. (1989) Combined modality treatment with radiotherapy and chemotherapy. Radioth. Oncol. 16, 83-101 https://doi.org/10.1016/0167-8140(89)90025-X
  42. Tannock, I. F. (1994) New perspectives in combined radiotherapy and chemotherapy treatment. Lung Cancer 10, 29-m51 https://doi.org/10.1016/0169-5002(94)91665-9
  43. Wong, L. C., Choo, Y. C., Choy, D., Sham, J. S., and Ma, H. K. (1989) Long-term follow-up of potentiation of radiotherapy by cis-platinum in advanced cervical cancer. Gynecol. Oncol. 35, 159-163 https://doi.org/10.1016/0090-8258(89)90035-8